Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial
Author:
Funder
Maruho Co., Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Dermatology
Link
https://link.springer.com/content/pdf/10.1007/s13555-023-00901-7.pdf
Reference45 articles.
1. Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464–74. https://doi.org/10.1111/bjd.16934.
2. Bacci E, Rentz A, Correll J, Pierce E, DeLozier A, Rueda M, et al. Patient-reported disease burden and unmet therapeutic needs in atopic dermatitis. J Drugs Dermatol. 2021;20(11):1222–30. https://doi.org/10.36849/jdd.6329.
3. Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279–86. https://doi.org/10.1007/s00403-013-1402-1.
4. Legat FJ. Itch in atopic dermatitis—what is new? Front Med (Lausanne). 2021;8: 644760. https://doi.org/10.3389/fmed.2021.644760.
5. Bawany F, Northcott CA, Beck LA, Pigeon WR. Sleep disturbances and atopic dermatitis: relationships, methods for assessment, and therapies. J Allergy Clin Immunol Pract. 2021;9(4):1488–500. https://doi.org/10.1016/j.jaip.2020.12.007.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials;The Lancet;2024-08
2. A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis;Journal of Clinical Medicine;2024-07-09
3. Interleukin antagonists for atopic dermatitis: a new era of therapy;Expert Opinion on Investigational Drugs;2024-06-02
4. Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives;Auris Nasus Larynx;2024-04
5. A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?;Dermatology and Therapy;2023-11-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3